Published on 20 Dec 2024 on Barrons.com
Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.
For more than a year, Novo Nordisk has told the world it expects patients to lose “at least 25%” of...
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free